Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
129 studies found for:    Open Studies | niaid
Show Display Options
Download search resultsDownload the search results for:
Open Studies | niaid (129 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Recruiting Interferon Responses in Eczema Herpeticum
Conditions: Atopic Dermatitis;   Eczema Herpeticum;   Herpes Simplex Infections;   Eczema Vaccinatum
Intervention:
2 Not yet recruiting Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: DNA-HIV-PT123 vaccine;   Biological: Bivalent Subtype C gp120/MF59 vaccine;   Biological: Bivalent Subtype C gp120/AS01B vaccine;   Biological: Placebo
3 Not yet recruiting Evaluating the Pharmacokinetics, Safety, and Tolerability of Bedaquiline in HIV-Infected and HIV-Uninfected Infants, Children, and Adolescents With Multidrug-Resistant Tuberculosis
Conditions: Tuberculosis;   HIV Infections
Intervention: Drug: Bedaquiline
4 Not yet recruiting Novel Mobile Device Application to Improve Adherence
Conditions: Pediatric Heart Transplant Recipients;   Pediatric Cardiac Transplantation;   Pediatric Heart Transplantation
Interventions: Device: TPP;   Other: Control Group
5 Recruiting Post‐Traumatic Stress Symptoms (PTSS) in Transplant Recipients
Conditions: Solid Organ Transplant Recipients;   Parent(s)/Guardian of Referenced Transplant Recipients
Intervention: Other: Assessment of adherence, mental health, behavioral, quality of life and biological constructs
6 Not yet recruiting Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants 6 to 24 Months of Age
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV LID cp ΔM2-2 Vaccine;   Biological: Placebo
7 Not yet recruiting Evaluating the Safety and Immunogenicity of a Live Attenuated Virus Vaccine to Prevent Influenza H3N2v Disease
Condition: Influenza
Interventions: Biological: H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV);   Biological: H3N2v inactivated subvirion influenza vaccine;   Biological: Placebo
8 Not yet recruiting Evaluating the Safety and Immunogenicity of a Tetravalent Dengue Vaccine (TetraVax-DV) TV005 in Flavivirus-Naive Adults 50 to 70 Years of Age
Condition: Dengue
Interventions: Biological: TetraVax-DV TV005;   Biological: Placebo
9 Not yet recruiting Partnership for Research on Ebola VACcinations
Condition: Ebola Virus Disease
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: rVSVΔG-ZEBOV-GP;   Biological: Placebo;   Biological: rVSV boost
10 Recruiting Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30
Condition: Dengue
Interventions: Biological: TetraVax-DV-TV005;   Biological: rDEN3Δ30;   Biological: Placebo
11 Not yet recruiting Evaluating the Immunogenicity of the AIDSVAX B/E Vaccine and the MVA/HIV62B Vaccine in Healthy, HIV-1-Uninfected Adults Who Previously Received MVA/HIV62B in DNA/MVA or MVA/MVA Regimens in HVTN 205
Condition: HIV Infections
Interventions: Biological: MVA/HIV62B vaccine;   Biological: AIDSVAX B/E vaccine;   Biological: Placebo
12 Not yet recruiting Evaluating the Safety, Pharmacokinetics, and Anti-Viral Activity of VRC01 and VRC01LS in the Serum and Mucosa of Healthy, HIV-Uninfected Adults
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: VRC01LS
13 Recruiting Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants 6 to 24 Months of Age
Condition: Respiratory Syncytial Virus Infections
Interventions: Biological: RSV LID ΔM2-2 1030s vaccine;   Biological: Placebo
14 Not yet recruiting Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection
Condition: HIV Infections
Intervention: Drug: Maraviroc
15 Recruiting Impact of Allo- and Autoantibodies on Chronic Cardiac Allograft Function
Conditions: Pediatric Heart Transplantation;   Pediatric Heart Transplant Recipients
Intervention:
16 Recruiting A Cohort Study of Operationally Tolerant Allograft Recipients
Conditions: Kidney Transplant;   Liver Transplant
Intervention: Procedure: Blood Draw
17 Not yet recruiting Impact of CCR5 Blockade in HIV+ Kidney Transplant Recipients
Condition: HIV Infections
Interventions: Drug: Maraviroc;   Drug: Placebo
18 Recruiting Type 1 Diabetes Extension Study
Conditions: Type 1 Diabetes;   Diabetes Mellitus
Intervention:
19 Not yet recruiting Safety and Efficacy Study of Injectable Cabotegravir Compared to Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine (TDF/FTC), For Pre-Exposure Prophylaxis in HIV-Uninfected Cisgender Men and Transgender Women Who Have Sex With Men
Condition: HIV Infections
Interventions: Drug: Cabotegravir tablets;   Drug: TDF/FTC tablets;   Drug: TDF/FTC placebo tablets;   Drug: CAB placebo tablets;   Drug: CAB LA;   Drug: Placebo for CAB LA
20 Recruiting Evaluating the Safety and Efficacy of the VRC01 Antibody in Reducing Acquisition of HIV-1 Infection Among Men and Transgender Persons Who Have Sex With Men
Condition: HIV Infections
Interventions: Biological: VRC01;   Biological: Placebo for VRC01

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years